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ORIGINAL RESEARCH
Kallikrein- 1 Blockade Inhibits Aortic 
Expansion in a Mouse Model and Reduces 
Prostaglandin E2 Secretion From Human 
Aortic Aneurysm Explants
Corey S. Moran, PhD; Erik Biros, PhD; Smriti M. Krishna , PhD; Susan K. Morton, PhD; Daniel J. Sexton, PhD;  
Jonathan Golledge , MChir
BACKGROUND: Abdominal aortic aneurysm (AAA) is an important cause of mortality in older adults. The kinin B2 receptor 
agonist, bradykinin, has been implicated in AAA pathogenesis through promoting inflammation. Bradykinin is generated from 
high- and low- molecular- weight kininogen by the serine protease kallikrein- 1. The aims of this study were first to examine the 
effect of neutralizing kallikrein- 1 on AAA development in a mouse model and second to test how blocking kallikrein- 1 affected 
cyclooxygenase- 2 and prostaglandin E2 in human AAA explants.
METHODS AND RESULTS: Neutralization of kallikrein- 1 in apolipoprotein E- deficient (ApoE−/−) mice via administration of a blocking 
antibody inhibited suprarenal aorta expansion in response to angiotensin (Ang) II infusion. Kallikrein- 1 neutralization decreased 
suprarenal aorta concentrations of bradykinin and prostaglandin E2 and reduced cyclooxygenase- 2 activity. Kallikrein- 1 neu-
tralization also decreased protein kinase B and extracellular signal- regulated kinase 1/2 phosphorylation and reduced levels 
of active matrix metalloproteinase 2 and matrix metalloproteinase 9. Kallikrein- 1 blocking antibody reduced levels of cyclooxy-
genase- 2 and secretion of prostaglandin E2 and active matrix metalloproteinase 2 and matrix metalloproteinase 9 from human 
AAA explants and vascular smooth muscle cells exposed to activated neutrophils.
CONCLUSIONS: These findings suggest that kallikrein- 1 neutralization could be a treatment target for AAA.
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Worldwide, abdominal aortic aneurysm (AAA) is estimated to be responsible for ≈200  000 deaths each year because of aortic rupture or 
complications of surgical repair.1 Most AAAs are iden-
tified when they are small and at low risk of rupture.2 
The natural history of most small AAAs is expansion 
to a size when surgical repair is required to prevent 
rupture. There is great current interest in identifying 
targets for the development of drug therapies that can 
effectively limit AAA growth and rupture.3– 6
Kinins are potent bioactive peptides key in regulating 
vascular permeability and inflammation following tissue 
injury.7 It has been previously reported that administra-
tion of a kinin- receptor agonist amplified the response 
to angiotensin II (AngII) and markedly promoted aortic 
rupture and severity of aortic dilatation within a mouse 
model of AAA.8 A kinin- receptor antagonist limited aneu-
rysm growth and reduced aortic rupture incidence in the 
same experimental model.8 These findings suggested 
that blocking kinin signaling could be a potential treat-
ment strategy to limit AAA progression, although how to 
achieve this most effectively and safely remains unclear.
Within tissues, such as blood vessels, the action of 
kallikrein- 1 (tissue kallikrein) releases the endogenous 
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kinin B2 receptor ligand bradykinin from either high- or 
low- molecular- weight kininogen.9,10 Kallikrein- 1 block-
ade could therefore be a feasible and potentially safe 
way to limit kinin receptor signaling and progression of 
AAA pathological processes.
The aim of this study was to test whether kallikrein- 1 
neutralizing antibodies limited AAA progression within 
the AngII- infused apolipoprotein E- deficient (ApoE−/−) 
mouse model. A secondary aim was to study whether 
kallikrein- 1 neutralizing antibodies limited release of 
pro- inflammatory cytokines and matrix remodeling en-
zyme from human AAA explant and vascular smooth 
muscle cells in vitro.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
Kallikrein- 1 Inhibitors
Neutralizing antibodies to mouse (M40- A03) and 
human (DX- 2300) kallikrein- 1 and corresponding IgG 
controls were kindly provided by Dr Daniel Sexton 
(Shire, United States; formerly of Dyax Corporation).
Mouse Model and In Vivo Study
Mouse studies were performed in accordance with insti-
tutional and ethical guidelines of James Cook University, 
Australia (Approval A1455) and conformed to the 
Australian code for the care and use of animals for scien-
tific purposes (8th Edition, 2013), the Guide for the Care 
and Use of Laboratory Animals (National Institutes of 
Health, USA) and the ARRIVE criteria set by The National 
Centre for the Replacement, Refinement and Reduction 
of Animals in Research (London, UK). All experimental 
procedures were conducted within the Small Animal 
Handling Facility, James Cook University, Australia.
Mice
Male apolipoprotein E- deficient mice (ApoE−/−) were 
purchased from The Animal Resources Centre, 
Western Australia and housed under a 12:12- hour 
light– dark cycle (relative humidity: 55%– 60%; tem-
perature: 22±1°C) in an individually Ventilated Cage 
unit (Tecniplast). Standard chow and water were pro-
vided ad libitum. Male mice were used because of the 
greater propensity for AngII- induced AAA.
Aortic Aneurysm Model
Aortic dilatation was induced in 6- month- old male 
ApoE−/− mice by subcutaneous infusion of AngII 
(1.0 µg/kg per minute) for 28 days as previously de-
scribed.8,11,12 Briefly, an osmotic micro- pump (ALZET 
Model 1004, Durect Corporation) containing AngII 
(#A9525, Merck) dissolved in sterile water was in-
serted into the subcutaneous space, left of the dorsal 
midline under general anaesthesia (4% isoflurane) to 
administer AngII at a rate of 1.0 μg/kg per minute over 
28 days.
Intervention
Mice were randomly allocated to intraperitoneal ad-
ministration of M40- A03 (10 mg/kg; n=15) or isotype 
control (n=15) commenced 24  hours before place-
ment of the AngII infusion pumps, then every 3 days 
over the 28- day AngII infusion period. Sudden mouse 
fatality required necropsy within 24 hours to confirm 
aortic rupture as the cause of death. Mice complet-
ing the study protocol were isoflurane- sedated be-
fore CO2- induced euthanasia. Harvested aortas were 
PBS- perfused and digitally photographed (Coolpix 
4500, Nikon).
Assessment of Suprarenal Aortic 
Dilatation
All outcome assessment was performed by an ob-
server blinded to group allocation. Aortic diameter 
was the primary outcome of the mouse experiment. 
CLINICAL PERSPECTIVE
What Is New?
• Neutralization of kallikrein- 1 inhibited experi-
mental aortic aneurysm formation in a mouse 
model through downregulating cyclooxyge-
nase- 2 and matrix metalloproteinase 2 and 9.
• In vitro neutralization of kallikrein- 1 reduced 
levels of cyclooxygenase- 2 and secretion of 
prostaglandin E2 and active matrix metallopro-
teinase 2 and 9 from human AAA explants.
What Are the Clinical Implications?
• Kallikrein- 1 may be a novel target for a drug 
therapy for aortic aneurysm.
Nonstandard Abbreviations and Acronyms
AKT protein kinase B
AngII angiotensin II
AoSMC aortic smooth muscle cell
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Ultrasound measurements of the suprarenal aorta 
(SRA; ie, aortic hiatus to the left renal artery) were 
obtained before AngII infusion (day 0) and then at 
days 14 and 28. Scans were performed in sedated 
mice (4% isoflurane) using a MyLabTM 70 VETXV 
platform (Esaote, Italy) with a 40- mm linear trans-
ducer at an operating frequency of 10 MHz (LA435; 
Esaote, Italy) to provide a sagittal image of the SRA. 
Maximum outer- to- outer- wall orthogonal SRA diam-
eter was measured at peak systole using the caliper 
measurement feature. Interobserver reproducibility of 
ultrasound analysis in our laboratory is excellent.13
Cell Culture
Preparation of Neutrophil- Derived Conditioned 
Media
Neutrophils from human- donor whole peripheral 
blood were purified by dextran T500 (551005009006, 
Pharmacosmos) centrifugation followed by Ficoll- 
Hypaque (1077, Merck) gradient centrifugation and 
hypotonic lysis of residual erythrocytes by red blood 
cell lysis buffer (00- 4333- 57, e- Bioscience). Cells were 
washed and resuspended with Hanks balanced salt 
solution (14025092, ThermoFisher Scientific) and 
used immediately for experiments. Trypan blue ex-
clusion demonstrated 98% cell viability. Purified neu-
trophils (1.2×106/mL) were incubated in the presence 
of either Hanks balanced salt solution (control), AngII 
(10 nmol/L; termed CM1), or AngII+kallikrein- 1 neutral-
izing antibody (DX- 2300; 5  μg/mL; termed CM2) for 
30 minutes at 37°C, 5% CO2, with the resulting con-
ditioned culture supernatant assayed for markers of 
neutrophil activation.
Vascular Smooth Muscle Cell Studies
Human aortic vascular smooth muscle cells (AoSMC; 
Lonza) were maintained in DMEM+10% fetal bovine 
serum at 37ºC, 5% CO2, at a density of 2×10
5 to 
1×106  cells/mL (passage 5– 8). Experimental AoSMC 
seeded at 5×104 cells/mL were rendered quiescent in 
serum- free medium (18 hours) before incubation under 
the following conditions: (1) control media; (2) control 
media+10% volume per volume (vol/vol) CM1; and (3) 
control media+10% vol/vol CM2. Cells harvested after 
24 hours were prepared for protein and gene expres-
sion analyses.
Human AAA Biopsies
Informed consent from male patients undergoing 
elective repair of 5- to 6- cm aneurysm allowed col-
lection of full- thickness biopsies from the maximally 
dilated region of the infrarenal aorta opposite the 
inferior mesenteric artery as previously described.14 
Tissue collection followed protocols approved by 
the ethics committees of the Townsville Hospital 
and Health Services and James Cook University in 
line with the Declaration of Helsinki guidelines. For 
explant culture studies, AAA body biopsies from 
each patient were dissected into two 100- mg full- 
thickness explants and stabilized in DMEM+10% fetal 
bovine serum at 37°C, 5% CO2. After 24 hours 1 of 
the 2 explants was incubated in the presence of the 
kallikrein- 1 neutralizing antibody DX- 2300 (50 μg/mL; 
n=6) while the second was incubated in fresh media 
with an isotype control (n=6), with tissue bradykinin 
and cyclooxygenase- 2, and secreted PGE2 (prosta-
glandin E2), active MMP2 (metalloproteinase 2), and 
MMP9 assayed after 72 hours.
Protein and Activity Analyses
Commercial assays were used as per manufacturer’s 
instruction to measure concentration and activity of 
target proteins including bradykinin, cyclooxyge-
nase- 2, PGE2, total and phosphorylated Akt1 (pro-
tein kinase B), total and phosphorylated ERK1/2 
(extracellular signal- regulated kinase), MMP2, 
MMP9, myeloperoxidase, calponin- 1, and retinol 
binding protein- 1 in mouse SRA, human AAA tissue, 
AoSMC, and neutrophil cell culture samples. Assays 
and corresponding targets are detailed in Table S1. 
Kallikrein- 1 activity was measured by cleavage of 
the selective substrate d- valyl- l- leucyl- l- arginine p- 
nitroanilide (d- Val- Leu- Arg- pNA; Merck). In a 96- well 
microplate, 25  μL of sample (0.4  μg/μL SRA pro-
tein from AngII- infused ApoE−/− mice administered 
M40- A03 or isotype control) was added to 50 μL of 
assay buffer (0.2  mol/L Tris- HCl, 0.01  mol/L EDTA, 
pH 8.2) and 25 μL of d- Val- Leu- Arg- pNA substrate 
(0.375 mmol/L). Absorbance at 405 nm was meas-
ured at 30- second intervals for 30 minutes (Sunrise 
Microplate Reader, Tecan). A standard curve was 
generated using a synthetic form of the reaction 
product (p- nitroaniline, 0– 50  nmol; Merck) meas-
ured colorimetrically at 420  nm (Sunrise Microplate 
Reader, Tecan). Kallikrein- 1 activity was expressed 
as micro- units per milligram protein where 1 unit (U) 
was defined as the amount of kallikrein- 1 required 
to hydrolyze 1 μmol of substrate per minute under 
assay conditions.
Real- Time Polymerase Chain Reaction
QuantiTect Primer Assays determined gene expres-
sion for prostaglandin- endoperoxide synthase 2, also 
known as cyclooxygenase- 2 (PTGS2; QT00040586), 
CNN1 (QT00067718), ERK1 (QT00065933), ERK2 
(QT02589321), AKT1 (QT00085379), Nuclear Factor 
Kappa B Subunit 1 (NFKB1; QT00063791), MMP2 
(QT00088396), and MMP9 (QT00040040) in human 
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reaction as previously described.15 The relative ex-
pression of these genes in experimental and control 
samples was calculated by using the concentration- 
Ct- standard curve method and normalized using 
the average expression of GAPDH (human GAPDH, 
QT00079247) for each sample using the Rotor- Gene 
Q operating software version 2.0.24. The QuantiTect 
SYBR Green one- step RT- PCR Kit (Qiagen) was used 
according to the manufacturer’s instructions with 
40 ng of total RNA as template. All reactions were in-
dependently repeated in duplicate.
Statistical Analysis
Data were analyzed using GraphPad Prism (version 
7) and TIBCO Spotfire S+ (version 8.2). D’Agostino 
and Pearson’s test was used to assess the normal-
ity of data and parametric or nonparametric tests 
applied appropriate to data distribution. Median and 
interquartile range with maximum and minimum points 
were presented. Student t or Mann– Whitney U tests 
were used for 2- group comparisons of parametric and 
nonparametric data, respectively. Repeated measures 
1- way ANOVA followed by Tukey’s multiple compari-
sons test (parametric) or Kruskal– Wallis test followed 
by Dunn’s multiple comparisons test (nonparametric) 
were used to compare data within each group ob-
tained as a function of time, with statistical significance 
between groups (control versus intervention) deter-
mined by mixed- effects linear regression. Contingency 
analyses used Fisher exact test. A P<0.05 was consid-
ered statistically significant in all cases.
RESULTS
Kallikrein- 1 Neutralization Limited AngII- 
Induced SRA Dilatation Associated With 
Lower SRA Bradykinin Concentration
Baseline mean maximum SRA diameter was similar in 
control and experimental mice (Figure S1). Both con-
trol and experimental mice exhibited a time- dependent 
increase in SRA diameter in response to AngII infu-
sion (Figure  1A). However, the rate of SRA dilatation 
was significantly less in mice administered kallikrein- 1 
neutralizing antibody (Figure 1B). None of the 15 mice 
receiving kallikrein- 1 neutralizing antibody had aortic 
rupture during the 28- day AngII infusion. In contrast, 
5 of the 15 (33%) control mice died of aortic rupture 
(P=0.042; Fisher exact test). Aortas harvested from 
surviving mice are shown in Figure S2. A significantly 
lower kallikrein- 1 activity and bradykinin concentration 
were found in the harvested SRA of mice receiving kal-
likrein- 1 neutralizing antibody compared with isotype 
control (Figure 1C and 1D), which confirmed the effi-
cacy of the neutralizing antibody in the mouse model.
Kallikrein- 1 Neutralization Reduced 
Cyclooxygenase- 2 Activity and 
Concentrations of PGE2 Within the SRA
Protein samples obtained from the SRA of mice ad-
ministered either the kallikrein- 1 neutralizing anti-
body or IgG control at completion of the study (day 
28) were assayed for cyclooxygenase- 2 activity and 
PGE2 concentration. SRA cyclooxygenase- 2 activity 
was markedly lower in mice administered the kallikrein-
 1 neutralizing antibody compared with IgG control 
(Figure 2A). Lower SRA concentrations of PGE2 were 
also found in mice administered kallikrein- 1 neutralizing 
antibody compared with controls (Figure 2B).
Akt/Erk Signaling was Downregulated 
and Active Gelatinases Reduced Within 
the SRA of Mice Administered Kallikrein- 1 
Neutralizing Antibody
Protein samples obtained from SRA samples were 
assayed for Akt1 and Erk1/2 phosphorylation and 
Mmp2 and Mmp9. The concentrations of total Akt1 
and Erk1/2 kinases within the SRA tissue of mice re-
ceiving kallikrein- 1 neutralizing antibody were similar to 
concentrations in control mice (Figure S3). In contrast, 
phosphorylated Akt1 and Erk1/2 were present at sig-
nificantly lower concentrations (Figure S3). The ratio of 
phosphorylated- to- total kinase (activity) for both Akt1 
and Erk1/2 within SRA tissue from mice administered 
kallikrein- 1 neutralizing antibody was significantly lower 
than that within SRA of control mice (Figure 2C and 
2D). Similarly, SRA concentrations of the active isoform 
of both Mmp2 and Mmp9 were significantly lower in 
mice administered kallikrein- 1 neutralizing antibody 
compared with control (Figure 2E and 2F).
Kallikrein- 1 Neutralizing Antibody 
Reduced Tissue Bradykinin Concentration 
and Cyclooxygenase- 2 Activity and 
Limited Secretion of PGE2 and Active 
Gelatinases in Human AAA Explants
Tissue and secreted levels of selected proteins were 
assessed in human AAA biopsies following 72 hours in 
explant culture in the presence or absence of human 
kallikrein- 1 neutralizing antibody. Median tissue con-
centration of bradykinin was 4- fold lower in explants 
exposed to kallikrein- 1 neutralizing antibody com-
pared with control (Table). Cyclooxygenase- 2 activity 
within biopsies incubated with kallikrein- 1 neutralizing 
antibodies was significantly lower compared with IgG 
controls (Table). Supernatant concentration of PGE2 
from biopsies incubated with kallikrein- 1 neutraliz-
ing antibody was 3- fold lower than control explants 
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MMP9 were significantly lower in biopsies incubated 
with kallikrein- 1 neutralizing antibody (Table).
Bradykinin Production in AngII- Stimulated 
Neutrophils Was Inhibited by Kallikrein- 1 
Neutralizing Antibody
The action of the human kallikrein- 1 neutralizing anti-
body on AngII- mediated activation of human neutro-
phils was investigated in vitro. Culture supernatants 
were assayed for myeloperoxidase, a hallmark indicator 
of the neutrophil respiratory burst, as a measure of neu-
trophil activation. Myeloperoxidase concentration within 
supernatants of neutrophils exposed to AngII was 5- fold 
above resting cells (P=0.002; Figure S4). Supernatant 
myeloperoxidase in AngII- stimulated neutrophils co- 
incubated with kallikrein- 1 neutralizing antibody re-
mained higher than resting cells and comparable to 
neutrophils stimulated with AngII alone (Figure  S4). 
Bradykinin production in AngII- stimulated neutrophils, 
however, was decreased 2- fold upon co- incubation 
with kallikrein- 1 neutralizing antibody (Table S2).
Figure 1. Effect of kallikrein- 1 blockade on bradykinin and dilatation of the SRA.
A, Ultrasound measurement of the SRA in AngII- infused ApoE−/− mice administered M40- A03 
(open circle) vs isotype control (closed circle). Data expressed as median and interquartile range 
with maximum and minimum data points (whiskers) for maximum SRA diameter (mm); P values 
calculated for difference between groups by mixed- effects linear regression. B, Severity of SRA 
dilatation at day 28 relative to day 0 (baseline) compared between mice receiving M40- A03 vs 
isotype control. Data expressed as median and interquartile range with maximum and minimum 
data points (whiskers) for percent increase in diameter. C, Kallikrein- 1 activity within the SRA of 
AngII- infused ApoE−/− mice receiving the kallikrein- 1 neutralizing antibody M40- A03 vs vehicle 
(control) after 28 days. Data expressed as median and interquartile range with maximum and 
minimum data points (whiskers) for micro- units (μU) of activity per milligram (mg) SRA protein. 
D, SRA tissue concentration of bradykinin at 28  days in AngII- infused ApoE−/− mice receiving 
the kallikrein- 1 neutralizing antibody M40- A03 vs vehicle control. Data expressed as median 
and interquartile range with maximum and minimum data points (whiskers) for picograms (pg) 
bradykinin per microgram (μg) SRA protein. Two- sided P value for comparison between control 
and experimental by Mann– Whitney U test. AngII indicates angiotensin II; ApoE−/−, apolipoprotein 
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Figure 2. Effect of kallikrein- 1 neutralization on cyclooxygenase- 2, PGE2, Akt, Erk, and 
Mmp activity.
Cyclooxygenase- 2 activity (A) and concentration of PGE2 (B) within the SRA of AngII- infused 
ApoE−/− mice administered M40- A03 vs vehicle (control) after 28 days. Data expressed as median 
and interquartile range with maximum and minimum data points (whiskers) for micro- units (μU) 
of activity per milligram (mg) SRA protein, or picograms (pg) per microgram (μg) SRA protein, 
respectively. Phosphorylation of Akt1 (C) and Erk1/2 (D) in SRA of AngII- infused ApoE−/− mice 
administered M40- A03 vs vehicle (control) after 28 days. Data expressed as median and interquartile 
range with maximum and minimum data points (whiskers) for quantitative relationship (ratio) between 
phosphorylated and total kinase. Concentration of active Mmp2 (E) and active Mmp9 (F) within the 
SRA of ApoE−/− mice administered M40- A03 vs vehicle (control) after 28 days. Data expressed as 
median and interquartile range with maximum and minimum data points (whiskers) for nanograms 
(ng) of active Mmp per microgram (μg) SRA protein. Two- sided P value for comparison between 
control and experimental by Mann– Whitney U test. AngII indicates angiotensin II; Akt, protein kinase 
B; ApoE−/−, apolipoprotein E- deficient mouse; Erk, extracellular signal- regulated kinase; MmP, 
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Response of Human AoSMC to 
Conditioned Media From AngII- Stimulated 
Neutrophils Incubated in the Presence 
or Absence of Kallikrein- 1 Neutralizing 
Antibody
Human AoSMC were incubated over 24  hours in 
control media, control media supplemented with 
10% vol/vol conditioned media from AngII- activated 
neutrophils (CM1), or control media supplemented 
with AngII- activated neutrophils co- incubated with 
kallikrein- 1 neutralizing antibody (CM2). Gene and 
protein expression associated with AoSMC phe-
notype and function was assessed. Exposure of 
AoSMC to CM1 stimulated an inflammatory response 
marked by a 10- fold upregulation in gene expression 
for nuclear factor kappa- light- chain- enhancer of ac-
tivated B cells and downregulation of the differentia-
tion marker calponin- 1 compared with control cells 
(Figure  S5). Incubation of AoSMC with CM2 over 
the same period resulted in a 3- fold decrease in nu-
clear factor kappa- light- chain- enhancer of activated 
B cells and concomitant downregulation in MMP2 
and MMP9 expression compared with CM1- exposed 
cells (Figure  3A through 3C). Gene expression for 
calponin- 1 was upregulated 2- fold and corresponded 
with a 3- fold increase in calponin- 1- to- retinol binding 
protein- 1 protein ratio in AoSMC incubated with CM2 
compared with CM1 (Figure 3D and 3E). In contrast, 
gene expression for cyclooxygenase- 2 was markedly 
downregulated in AoSMC incubated with CM2 and 
associated with significant decrease in cyclooxyge-
nase- 2 activity and a 3- fold reduction in PGE2 con-
centration in these cells (Figure 3F through 3H).
DISCUSSION
The main finding of this study was that kallikrein- 1 
neutralization blocked several processes strongly 
implicated in AAA pathogenesis, including cycloox-
ygenase- 2 and MMP activity. These effects were 
consistent in a mouse model, human AAA explants, 
and AoSMC. The effects of kallikrein- 1 neutralization 
translated into significantly limiting the size of the AAAs 
Figure 3. In vitro response of human AoSMCs to conditioned media from AngII- activated human neutrophils.
Human AoSMC were incubated over 24  hours in media supplemented with 10% vol/vol conditioned media from AngII- activated 
neutrophils (CM1) or media supplemented with AngII- activated neutrophils co- incubated with kallikrein- 1 neutralizing antibody (CM2). A 
through C, Gene expression for pro- inflammatory markers NFKB1, MMP2, and MMP9. Data expressed as median and interquartile range 
with maximum and minimum data points (whiskers) for gene expression relative to GAPDH. D, Gene expression for contractile (quiescent) 
smooth muscle cell phenotype marker CNN1. Data expressed as median and interquartile range with maximum and minimum data points 
(whiskers) for gene expression relative to GAPDH. E, Protein ratio for contractile phenotype marker CNN1 to synthetic phenotype marker 
RBP1 as a measure of phenotype status. Data expressed as median and interquartile range with maximum and minimum data points 
(whiskers) for picograms of CNN1- to- RBP1 (ratio) per microgram of protein. F through H, Gene expression (F) and cellular activity for 
cyclooxygenase- 2 (G) and secreted levels of PGE2 (H). Data expressed as median and interquartile range with maximum and minimum 
data points (whiskers) for gene expression relative to GAPDH, micro- units (μU) of activity per milligram (mg) of protein and picograms 
(pg) per milliliter (mL) supernatant. Two- sided P value for comparison between control and experimental groups by Mann– Whitney U test. 
AngII indicates angiotensin II; AoSMC, aortic smooth muscle cell; CNN1, calponin- 1; MMP, matrix metalloproteinase; NFKB1, nuclear 
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that developed and the number of AAAs that ruptured 
in a mouse model. Overall, the findings suggest that 
blocking kallikrein- 1 is a potential target to limit AAA 
progression.
Genome- wide DNA linkage analyses of families 
in which 2 or more members had an AAA previously 
identified a genomic region on chromosome 19q13 to 
be associated with AAA.16,17 This region contains the 
gene encoding kallikrein- 1.16 In a subsequent study, a 
single nucleotide mutation in exon 3 of the kallikrein- 1 
gene was reported to be associated with large AAA.18 
In a prior experimental study, it was found that an ag-
onist for the B2 kinin receptor promoted the ability 
of AngII to induce AAA development and rupture.8 
Conversely, a B2 kinin antagonist inhibited AngII or 
calcium phosphate– induced aortic expansion.8 These 
findings in a mouse model and patients identified ki-
nins as potentially involved in AAA pathogenesis.
Kinins can be generated from kininogen by both 
plasma and tissue kallikrein. Plasma kallikrein is re-
leased from pre- kallikrein by activated Factor XII. It 
was previously reported that Factor XII deficiency or 
inhibition significantly reduced AngII- induced aortic 
expansion in ApoE−/− mice.12 The current study adds 
to this prior research by showing that the inhibition of 
kallikrein- 1 also significantly limited AAA development. 
Since kallikrein- 1 is expressed directly in the aorta and 
potentially has less wide- ranging effects than plasma 
kallikrein, it seems likely that it may be a safer target for 
a potential AAA drug.
Figure 4. Potential pathways by which inhibition of kallikrein- 1 may limiting AAA pathogenesis.
Schematic illustrating the potential relationship between vascular smooth muscle cell (VSMC) phenotypic switching induced by 
neutrophil- derived bradykinin (BK) stimulation of the kinin B2 receptor (B2R) and AAA. BK- mediated upregulation of cyclooxygenase- 2 
gene expression and activity in dedifferentiated VSMC is associated with increased PGE2 and production of active MMP2 and MMP9. 
Blockade of the neutrophil kallikrein- kinin pathway and subsequent BK generation via kallikrein- 1- neutralizing antibodies (M40- A03, 
DX- 2300) limits VSMC dedifferentiation, preserving the quiescent (contractile) phenotype. AAA indicates abdominal aortic aneurysm; 
AngII, angiotensin II; COX- 2, cyclooxygenase- 2; HMWK, high molecular weight Kininogen; KLK1, kallikrein- 1; LMWK, low molecular 
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Past mouse model and human research has impli-
cated cyclooxygenase- 2 in AAA pathogenesis.19– 25 Both 
cyclooxygenase- 2 deficiency22 and inhibition20,23 have 
been reported to inhibit AngII- induced AAA formation. 
Nonselective cyclooxygenase inhibition has also been re-
ported to inhibit elastase perfusion- induced AAA forma-
tion.24 The expression of cyclooxygenase- 2 and secretion 
of PGE2 have been reported to be greater in samples from 
ruptured compared with intact human AAAs.19,25 In these 
previous studies, cyclooxygenase- 2 has been identified 
both in infiltrating inflammatory cells and AoSMC.21,22 
Bradykinin has been previously reported to upregulate 
cyclooxygenase- 2 expression and activity within AoSMC 
and neutrophil cell lines in vitro.26,27 This past research 
suggested that kinins might promote AAA via upregulat-
ing cyclooxygenase- 2 and secretion of PGE2.
In the current study, kallikrein- 1 neutralization was 
effective in decreasing bradykinin levels in both the 
AngII mouse model and human AAA explants. This was 
associated with reduced cyclooxygenase- 2 expression 
and activity, and reduced production of PGE2 and ac-
tive MMP2 and MMP9. These effects were also found 
when neutrophils were exposed to kallikrein- 1 neutral-
ization and subsequently incubated with AoSMC, sug-
gesting that these cells were an important source of 
bradykinin, as previously described.28 Neutrophils pos-
sess the complete apparatus for synthesis and release 
of kinins.29 Kallikrein- 1 released by activated neutrophils 
converts kininogen on the neutrophil surface to brady-
kinin, promoting inflammation.29 Decreased production 
of bradykinin within the SRA, because of neutraliza-
tion of neutrophil kallikrein- 1, likely limited B2 receptor- 
mediated AoSMC activation and AngII- stimulated 
aortic remodeling. Support for this theory was provided 
by the results of the in vitro study, which showed that 
bradykinin production by AngII- stimulated neutrophils 
was blocked in the presence of the kallikrein- 1 neu-
tralizing antibody. Furthermore, phenotype switching 
of AoSMC, evidenced by upregulation of CNN1 and 
increased calponin- 1:retinol binding protein- 1 ratio and 
downregulation of NFκB1, MMP2, and MMP9, was in-
hibited by kallikrein- 1 neutralizing antibody. Overall, the 
findings of the current study and prior investigations 
suggest that blocking neutrophil- derived kinins is a po-
tential target to limit AoSMC phenotypic switching and 
aortic inflammation and remodeling believed to be key 
in AAA pathogenesis as outlined in Figure 4.8
The current study has several strengths and lim-
itations. Strengths include the combination of mouse 
model, human sample explant, and in vitro research. 
Limitations include that only 1 mouse model was 
studied. A control group that did not receive angio-
tensin II was not included in the current study since 
the focus was on testing kallikrein- 1 blockade during 
advanced aortic pathology. Tissue samples examined 
in the current study were collected from the end of the 
experiment. It is therefore possible that effects of the 
kallikrein- 1 inhibition at an earlier stage of aneurysm 
development might have been missed. Furthermore, 
gene expression and protein quantification were used 
to examine aortic samples. Samples were not exam-
ined by histology, which might have provided additional 
experimental insight. Also, it remains unproven beyond 
doubt that the benefits of kallikrein- 1 neutralization 
identified were directly caused by cyclooxygenase- 2 
inhibition. Other mechanisms not studied in this inves-
tigation might also have contributed. It should also be 
noted that the reported findings remain experimental 
and their translation to patients remains to be proven.
In conclusion, the current study, building on past 
evidence, suggests that kallikrein- 1 neutralization 
through reducing generation of bradykinin and ac-
tions of cyclooxygenase- 2 limit AAA development in a 
mouse model induced through AngII infusion.
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Table S1. Commercial assays used in this study. 
 
Model/Source Target Assay Manufacturer 














ELISA; ab176660  
Enzyme; QZBmmp2M 
Enzyme; QZBmmp9M 

































ELISA;  ab133021 
 
ThermoFisher Scientific 
Enzo Life Sciences 
 
Aviva Systems Biology 
























SRA, suprarenal aorta; PGE2, prostaglandin E2; Akt1, total and phosphorylated protein 
kinase B; Erk1/2, total and phosphorylated extracellular signal-regulated kinase 1/2; MMP, 
metalloproteinase; MPO, myeloperoxidase; AoSMC, aortic smooth muscle cell; CNN1, 









Table S2. Effect of kallikrein-1 neutralisation (DX-2300) on AngII-stimulated activation 
and bradykinin production in human neutrophils in vitro.  
Supernatant AngII AngII + DX-2300  P 
n (cultures) 6 6   
MPO† 0.43 (0.39-0.51) 0.37 (0.34-0.43) - 0.076 
Bradykinin‡ 108 (100-114) 76 (68-92) ↓ 0.004 
AngII, angiotensin II; MPO, myeloperoxidase; Data expressed as median (interquartile 
range) relative fluorescence units per microgram protein†, or picograms per microgram 
protein‡; P, two-sided p-value for comparison between control and experimental by Mann-
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Figure S1. Baseline (prior to AngII infusion) suprarenal aortic diameter at peak systole 
measured by ultrasound in ApoE-/- mice allocated to control and intervention (M40-A03) 
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Figure S2. Gross morphology of aortas harvested from AngII-infused ApoE-/- mice 
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Figure S3. Protein concentration of total protein kinase B (Akt; A), total extracellular signal-
regulated kinase (Erk)1/2 (B), phosphorylated Akt (C), and phosphorylated Erk 1/2 (D) 
kinases within SRA tissue of mice receiving kallikrein-1-neutralising antibody (M40-A03) or 
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Myeloperoxidase (MPO) activity assessed in supernatant of human neutrophils cultured for 30 
minutes in the presence/absence of AngII (10 nM) or the kallikrein-1 neutralising antibody DX-
2300 (5 μg/ml). Data expressed as median and interquartile range with maximum and minimum 
data points (whiskers) for relative fluorescence units (RFU) per μg protein from six repeat cultures. 
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mRNA expression for pro-inflammatory marker nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFKB1) and quiescent phenotype marker calponin-1 (CNN1) in AoSMC 
following incubation over 24 hours in 10% v/v conditioned media derived from AngII-stimulated 
neutrophil cultures (grey bar), compared to control media (white bar). Data expressed as median 
and interquartile range with maximum and minimum data points (whiskers) for gene expression 
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